Actively Recruiting
Evaluating the Safety and Effects of AZD6750 Alone or with Rilvegostomig in Adults with Advanced or Metastatic Solid Tumors
Led by AstraZeneca · Updated on 2026-10-08
120
Participants Needed
13
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying AZD6750, a CD8 guided IL-2 agent, to evaluate its safety, how it moves and acts in the body, and its effects alone and combined with other anti-cancer drugs. This study focuses on adults with select advanced or metastatic solid tumors, including melanoma, non-small cell lung cancer, and other specified cancers. It is an open-label Phase III trial that includes dose escalation and expansion phases to explore these treatments. Participants receive AZD6750 intravenously either alone or combined with rilvegostomig, a PD1-TIGIT bispecific antibody. The study consists of two modules Module 1 involves AZD6750 as a single agent for various solid tumors, and Module 2 evaluates AZD6750 combined with rilvegostomig specifically in participants with stage IV non-small cell lung cancer, including dose escalation and expansion groups. Treatment cycles vary between 21 and 28 days depending on the dosing schedule. During the trial, participants undergo safety assessments from consent until 90 days after the last dose. Efficacy is monitored every 6 weeks for 48 weeks, then every 12 weeks up to approximately two years or until disease progression or death. Additional evaluations include pharmacodynamics through biopsies, immunogenicity tests, and pharmacokinetics at defined intervals. Participants are closely monitored for side effects and treatment responses throughout the study duration.
CONDITIONS
Brief Title
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Research Team
A
AstraZeneca Clinical Study Information Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here